Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sitryx Therapeutics
Sitryx to Participate in Upcoming Investor Conferences
October 21, 2026
Sitryx Reports Positive Phase 1b Results for First-in-Class Oral PKM2 Modulator SYX-5219 in Patients with Moderate to Severe Atopic Dermatitis
October 13, 2026
Sitryx to Participate in Upcoming Investor Conferences
September 2, 2026
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis
June 22, 2026
Sitryx to Participate in Upcoming Investor Conferences
May 25, 2026
First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
May 13, 2026